newsfilter
← Latest News
Business Wire·

4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

- Study to assess safety of MRx0518 with BAVENCIO and effect on progression-free survival at 6 months- Study sites are open for patient enrolment 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Bioth